N/A N=240 Coping Together After Breast Cancer
Breast Cancer
Primary: Change in Self-Reported Patient Sexual Function — 6.41; 0.90 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Comparison of Alignment Achieved Using the VELYS Robotic-Assisted Solution Versus Manual Instrumentation in Total Knee Arthroplasty
Osteo Arthritis Knee · Osteoarthritis
Primary: Accuracy of the Hip-Knee-Ankle Angle (HKA) Measured on Long-leg X-rays at 12 Weeks. — 2.2; 2.5 Degrees — p=<0.0001
N/A N=63 Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations
COPD · Emphysema
Primary: Change in Chronic Respiratory Questionnaire (CRQ) Dyspnea Score — 0.29; -0.26 score on a scale
N/A N=9 Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy
Emphysema
Primary: Count of Patients With Grade 3 or Higher Adverse Events. — 3 Participants
N/A N=45 Palliative Care Consultations in the Skilled Nursing Facility (SNF) Setting
Palliative Care · Advance Care Planning · Skilled Nursing Facilities
Primary: Number of Participants Who Completed Patient Quality of Life Surveys — 10; 35; 10; 35 participants
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants
Phase 2 N=66 Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
Malaria
Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants
Phase 2 N=63 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Thyroid Cancer · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · HRAS Mutant Tumor
Primary: Antitumor Activity by Objective Response Rate (ORR) — 0.0; 0.0; 43.5; 28.6 percentage of participants
Phase 2 N=46 Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil
Healthy
Primary: Tolerance to Simulated Hemorrhage — 599; 651 min*mmHg
N/A N=50 Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer
Breast Neoplasms
Primary: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity — 50; 49 Participants
N/A N=12 Integration of DBT Skills and Parent Training for Parents With a History of Substance Use
Parenting · Substance Abuse Relapse · Emotional Regulation
Primary: Parental Emotion Dysregulation - The Difficulties With Emotion Regulation Scale (DERS) — 109.50; 68.80 units on a scale
N/A N=120,722 Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
Non-valvular Atrial Fibrillation
Primary: Incidence Rate Per 1000 Participant-Years For First Occurrence of Composite Stroke and Systemic Embolism (SE) Events After Index Date: Balanced Cohorts — 61.352; 75.078…
Phase 2 N=50 FLT-PET Imaging of Brain Tumors in Children
Brain Neoplasms
Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001
N/A N=1,464 Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Opioid Abuse · Prescription Drug Abuse (Not Dependent)
Primary: Validity of the PDMP Narcotic Score Versus the WHO ASSIST — .70; .74 probability
Phase 2 N=51 Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
Hypertension · Osteonecrosis · Osteonecrosis Due to Drug
Primary: Extensive Radiographic Osteonecrosis — 20; 21; 1; 2 Participants — p=0.7139